| Active Market | Forge Price1 | Last Funding Round | Trade Eligibility | ||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Company | Sector & Subsector | Market Activity4   |
Highest Bid | Lowest Ask | Last Matched | +/- to LFR | $ Total Bids |
$ Total Asks |
# Bids |
# Asks |
Current Price |
6-month |
1-year |
Total Funding |
Round | Date | Amount Raised |
Post-Money Valuation3 |
Price |
Key Investors | Common | Preferred | Fund | ||
 | Arthrosi Therapeutics | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $294.54M | Series E | 10/8/2025 | $148.1M | $385.03M | $6.54 | Prime Eight Capital, CR Biotech, HighLight Capital, HM Venture Partners, ReliantTech | ||||
 | Attralus | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $344M | Series B | 2/6/2024 | $172.6M | $428.81M | $7.76 | Logos Capital, Janus Henderson Investors, Redmile Group, Samsara BioCapital, Sarissa Capital Management, Surveyor Capital, Vivo Capital, venBio Partners, Alpha Wave Ventures, Bristol Myers Squibb | ||||
 | cAMPfield Therapeutics | Healthcare Other Healthcare | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $180M | Series A | 6/18/2026 | $177.98M | $297.85M | $5.22 | Frazier Life Sciences, Deep Track Capital, Forbion, Abingworth, Venrock, Longitude Capital, Novo Holdings, RA Capital | ||||
 | Cantex Pharmaceuticals | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $67.87M | Series D | 11/24/2014 | $34.31M | $276.31M | $0.96 | Undisclosed Investors | ||||
 | Chroma Medicine | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $262M | Series B | 3/1/2023 | $135M | $450.56M | $2.60 | ARCH Venture Partners, DCVC Bio, Mubadala Capital, Sixth Street, Alexandria Venture Investments, Atlas Venture, Casdin Vapital, Cormorant Asset Management, Janus Henderson Investors, Newpath Partners, Omega Funds, Osage University Partners, Sofinnova Partners, T Rowe Price, Wellington Management | ||||
 | Codoxo | Healthcare Healthcare Software | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $75M | Series C | 12/17/2025 | $35M | $275.36M | $13.93 | CVS Health Ventures, Echo Health Ventures, Sands Capital Management, 111 West Capital, Brewer Lane Ventures, Wipro Ventures, 450 Ventures, QED Investors | ||||
 | CoRegen | Healthcare Other Healthcare | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $131.81M | Series B-1 | 10/28/2025 | $13.5M | $431.58M | $18.00 | Undisclosed Investors | ||||
 | Courier Health | Healthcare Healthcare Software | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $70.45M | Series B-1 | 4/22/2026 | $45.97M | $264.59M | $21.50 | Oak HC/FT, Norwest, Work-Bench | ||||
 | Culture | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $142.12M | Series C-2 | 12/16/2025 | $20.52M | $60.79M | $0.29 | Northpond Ventures, Synthesis Capital, S32, Cultivian Sandbox | ||||
 | Dewpoint | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $354.6M | Series D | 9/10/2025 | $59.12M | $136.62M | $0.23 | 120 Capital | ||||
 | Elucid Bioimaging | Healthcare Healthcare Software | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $156.63M | Series D | 10/10/2025 | $36.5M | $316.49M | $2.13 | Undisclosed Investors | ||||
 | Engrail Therapeutics | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $215.08M | Series B-4 | 4/7/2025 | $10M | $275.98M | $1.06 | Undisclosed Investors | ||||
 | Eureka Therapeutics | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $130.85M | Series E | 12/16/2019 | $45M | $359.7M | $4.16 | Lyell Immunopharma, Acorn Pacific Ventures, GP Capital, Suma Venture, Harbinger Venture Capital, Yuan Capital, Majuven | ||||
 | Flagler Health | Healthcare Healthcare Providers & Services | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $62.75M | Series B | 8/11/2026 | $50M | $238.83M | $10.39 | Bessemer Venture Partners, SignalFire, Alumni Ventures, Streamlined, 186 Ventures, PROOF, Tribeca Venture Partners, Offscript | ||||
 | Flare Therapeutics | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $290.35M | Series C | 6/30/2026 | $85M | $188.49M | $0.37 | Third Rock Ventures, Nextech Invest, Pfizer, Boxer Capital, GordonMD Global Investments, Invus, Casdin Capital, Eli Lilly and Company, Novartis, Agent Capital, Eventide Asset Management | ||||
 | Geneoscopy | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $163.58M | Series C | 1/8/2025 | $79.05M | $447.85M | $4.13 | Bio-Rad Laboratories, Petrichor, Labcorp, Morningside Ventures, Lightchain Capital, NT Investments, Granger Management, Mercy Health, Tri Locum Partners | ||||
 | Georgiamune | Healthcare Other Healthcare | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $167.69M | Series B-1 | 7/16/2026 | $64.09M | $407.96M | $11.11 | Undisclosed Investors | ||||
 | HI-Bio | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $22.2M | Series A | 10/20/2022 | $20M | $97.78M | $0.71 | Tom Brown, Jonas Schneider, Drew Houston, Arash Ferdowsi, Astera Institute | ||||
 | Homeward Health | Healthcare Healthcare Providers & Services | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $100.4M | Series B-1 | 8/20/2026 | $30.4M | $398.59M | $12.85 | Undisclosed Investors | ||||
 | Inflammatix | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $186.19M | Series E-2 | 9/12/2024 | $26.2M | $210.31M | $0.15 | Khosla Ventures, Think.Health Ventures, Northpond Ventures, D1 Capital Partners, Iberis Capital, Vesalius BioCapital, OSF Healthcare Ventures, RAW Ventures | ||||
 | LeanTaaS | Healthcare Healthcare Software | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $214.7M | Series D-2 | 12/10/2020 | $99.66M | $491.79M | $12.72 | Insight Venture Partners, Goldman Sachs | ||||
 | NowRx | Healthcare Healthcare Providers & Services | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $114.11M | Series C | 10/7/2021 | $74.03M | $334.19M | $10.50 | Undisclosed Investors | ||||
 | Ophelia | Healthcare Healthcare Providers & Services | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $39.71M | Series AA | 3/7/2025 | $15M | $103.93M | $3.09 | Undisclosed Investor | ||||
 | Opyn Market | Healthcare Healthcare Providers & Services | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $162M | Series D | 3/27/2024 | $40M | $124.73M | $1.00 | Undisclosed Investors | ||||